

ALESSANDRO ISIDORI, MD, PhD.

June 2016

PERSONAL DATA

Date and Place of Birth: November, 12th 1974; Forlì (Italy)

Permanent Address:

via Ravaladini, 7
47035 Gambettola
Cesena
ITALY

(+39) 0547 53379 Phone
(+39) 347 0015894 Mobile

E-mail: aisidori@gmail.com
alessandro.isidori@ospedalimarchenord.it

Professional Address:

Hematology and Stem Cell
Transplant Center
Marche Nord Hospital
via Lombroso, 9
61100 Pesaro
ITALY

(+39) 0721 364022 Phone
(+39) 0721 364026 Fax

EDUCATION

*Current professional
position*

Attending Physicians, since November 16th, 2005

Hematology and Stem Cell Transplant Center, Marche Nord Hospital,
Pesaro, Italy

March 2008

Doctorate of Philosophy, Clinical and Experimental Hematology.

Institute of Hematology and Medical Oncology “L. & A. Seràgnoli” –
University of Bologna, Italy

November 2004

Fellowship in Hematology, summa cum laude.

Institute of Hematology and Medical Oncology “L. & A. Seràgnoli” –
University of Bologna, Italy
Alma Mater Studiorum – University of Bologna, Italy

October 1999

Degree in Medicine, summa cum laude.

Alma Mater Studiorum – University of Bologna, Italy

April 1997 – January 2000

Internship, Clinical and Experimental Hematology.

Institute of Hematology and Medical Oncology “L. & A. Seràgnoli” –
University of Bologna, Italy

**Co-author of 81 full-papers published on Journals quoted in the
Current Contest Index (Total Impact Factor >400, H-index 23, i-
10 index 37)**

Co-Author of 5 book chapters on Hematological subjects.

Co-author >200 abstracts published on Journals quoted in the Current Contest Index

Co-investigator in several Phase I-II-III clinical trials performed under GCP-ICH since 1999

Medical License number 2458 (Ordine dei Medici di Pesaro e Urbino) approved in June 2000

RESEARCH INTERESTS

- Acute myeloid leukemia.
- High-dose therapy and autologous stem cell transplantation in hematological malignancies.
- Non-Hodgkin lymphomas.
- Chronic lymphocytic leukemia.

MEMBERSHIP IN PROFESSIONAL SOCIETIES

- Member of the European Hematology Association (EHA) since 2005.
- Member of the American Society of Hematology (ASH) since 2006.
- Member of the European Bone Marrow Transplant Society (EBMT) since 2015.
- Member of the American Association for Cancer Research (AACR) (2014-2015).
- Member of the International Society for Experimental Hematology (ISEH) (2006-2008).
- Member of the Italian Society of Hematology (SIE) and of the Italian Society for Experimental Hematology (SIES) (2003-2010)
- Member of the American Society for Blood and Marrow Transplantation(ASBMT) (2003-2011).
- Founding Member of the Stem Cell Research (SCR) Italy (2009-2012)

AWARDS

June 2005 Winner of the European Hematology Association Clinical Research Grant , awarded during the Opening Ceremony of the 10th EHA International Congress in Stockholm, Sweden, on June 2nd, 2005, for the project “*Adoptive immunotherapy of high risk acute myeloblastic leukemia patients using haploidentical KIR ligand-mismatched Natural Killer cells*”.

SCIENTIFIC ACTIVITY

- Reviewer for The Lancet Haematology
- Reviewer for the British Journal of Haematology
- Reviewer for the European Journal of Hematology
- Reviewer for Leukemia and Lymphoma
- Member of the Editorial Board of Leukemia Research and Treatment.
- Member of the Editorial Board of the World Journal of Transplantation.
- Member of the Editorial Board of the World Journal of Stem Cells.
- Member of the Editorial Board of the American Journal of Blood.
- Member of the Editorial Board of Biomed Research international.
- Member of the Editorial Board of Frontiers Oncology

FOREIGN LANGUAGE SKILLS

- Italian (native speaker)
- English

SHORT BIOGRAPHY

Dr Alessandro Isidori is an Attending Physician in the Hematology and Stem Cell Transplant Center at the Marche Nord Hospital, Pesaro, Italy. He graduated medical school in 1999 from the Bologna University School of Medicine, where he also obtained his specialisation in Haematology and Medical Oncology in 2004 after a 7-year internship, and his PhD in Clinical and Experimental Haematology in 2008.

He is involved in many clinical trials for the treatment of chronic and acute leukaemias, lymphomas, and stem cell mobilisation and transplantation. He has also worked extensively in the area of cell therapy at the Centre for Stem Cell Research at the University of Bologna.

Dr Isidori's research has led to the co-authorship of more than 75 publications in peer-reviewed journals and five book chapters on haematological malignancies. In addition to his active research and clinical roles, he acts as a reviewer and is a member of the editorial boards for several well-regarded journals.

Dr Isidori was awarded with the European Hematology Association (EHA) clinical research grant during the opening ceremony of the 10th EHA International Congress (Stockholm, Sweden) in 2005. He is also a member of the American Society for Blood and Marrow Transplantation, the EHA, the American Society of Hematology and the American Association for Cancer Research.

PUBLICATIONS

1. Tripodo C, Burocchi A, Piccaluga PP, Chiodoni C, Portararo P, Cappetti B, Botti L, Gulino A, **Isidori A**, Liso A, Visani G, Martelli MP, Falini B, Pandolfi PP, Colombo MP, Sangaletti S. Persistent immune stimulation exacerbates genetically-driven myeloproliferative disorders via stromal remodeling. *Cancer Res.* 2017 May 23. pii: canres.1098.2017. doi: 10.1158/0008-5472.CAN-17-1098. [Epub ahead of print]
2. Palandri F, Tiribelli M, Benevolo G, Tieghi A, Cavazzini F, Breccia M, Bergamaschi M, Sgherza N, Polverelli N, Crugnola M, **Isidori A**, Binotto G, Heidel FH, Buccisano F, Martino B, Latagliata R, Spinsanti M, Kallenberg L, Palumbo GA, Abruzzese E, Scaffidi L, Cuneo A, Cavo M, Vianelli N, Bonifacio M. Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study. *Hematol Oncol.* 2017 May 17. doi: 10.1002/hon.2429. [Epub ahead of print]
3. Visani G, Manti A, Valentini L, Canonico B, Loscocco F, **Isidori A**, Gabucci E, Gobbi P, Montanari S, Rocchi M, Papa S, Gatti AM. Environmental nanoparticles are significantly over-expressed in acute myeloid leukemia. *Leuk Res.* 2016 Sep 3;50:50-56. doi: 10.1016/j.leukres.2016.09.004. [Epub ahead of print]
4. **Isidori A**, Loscocco F, Guiducci B, Malerba L, Clissa C, Visani G. Enteric-coated mycophenolate sodium: a new option for GHVD prophylaxis? *Eur J Haematol*, in press

5. **Isidori A**, Christofides A, Visani G. Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning. *Leuk Lymphoma*. 2016 Nov;57(11):2499-2509. Epub 2016 May 31.
6. Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, Fava C, Ferrero D, Gozzini A, Bonifacio M, Tiribelli M, Pregno P, Stagno F, Vigneri P, Annunziata M, Cavazzini F, Binotto G, Mansueto G, Russo S, Falzetti F, Montefusco E, Gugliotta G, Storti S, D'Addosio AM, Scaffidi L, Cortesi L, Cedrone M, Rossi AR, Avanzini P, Mauro E, Spadea A, Celesti F, Giglio G, **Isidori A**, Crugnola M, Calistri E, Sorà F, Rege-Cambrin G, Sica S, Luciano L, Galimberti S, Orlandi EM, Bocchia M, Tettamanti M, Alimena G, Saglio G, Rosti G, Mannucci PM, Cortelezzi A. Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. *Oncotarget*. 2016 Aug 27. doi: 10.18632/oncotarget.11657. [Epub ahead of print]
7. **Isidori A**, Loscocco F, Ciciarello M, Visani G, Corradi G, Forte D, Lecciso M, Ocadlikova D, Parisi S, Salvestrini V, Parolini M, Cavo M and Curti A. Renewing the immunological approach to AML treatment: from novel pathways to innovative therapies. *Cancer Research Frontiers*. 2016 May; 2(2): 226-251. doi: 10.17980/2016.226
8. Breccia M, Abruzzese E, Iurlo A, Gozzini A, **Isidori A**, Gangemi D, Pregno P, Alimena G. Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase. *Haematologica*. 2016 Jun;101(6):e267-8.
9. **Isidori A**, Loscocco F, Visani G. AML therapy in the elderly: a time for a change. *Expert Opin Drug Saf*. 2016 Jul; 15(7):891-2.
10. **Isidori A**, Loscocco F, Guiducci B, Malerba L, Clissa C, Visani G. PBSC mobilization in patients with autoimmune diseases: what's next. *Eur J Haematol*, *Eur J Haematol*. 2016 Jul;97(1):5-6.
11. **Isidori A**, Clissa C, Loscocco F, Guiducci B, Barulli S, Malerba L, Gabucci E, Visani G. Advancement in high dose therapy and autologous stem cell rescue in lymphoma. *World Journal of Stem Cells*, 2015 2015 Aug 26;7(7):1039-46. doi: 10.4252/wjsc.v7.i7.1039.
12. Visani G, Loscocco F, **Isidori A**. Nanocarriers targeting cancer stem cells: how to help drugs to find their way home. *Nanomedicine (Lond)*. 2015 Apr;10(7):1043-6.
13. Visani G, Stefani PM, Capria S, Malerba L, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Gonella R, Gobbi M, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Loscocco F, **Isidori A**. Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. *Blood*. 2014 Nov 6;124(19):3029-31.
14. **Isidori A**, Salvestrini V, Ciciarello M, Loscocco F, Visani G, Parisi S, Lecciso M, Ocadlikova D, Rossi L, Gabucci E, Clissa C, Curti A. The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment. *Expert Rev Hematol*. 2014 Dec;7(6):807-18.

15. Visani G, Loscocco F, **Isidori A**. Nanomedicine strategies for hematological malignancies: what's next. *Nanomedicine (Lond)*. 2014, 2014 Oct;9(15):2415-28.
16. Breccia M, Luciano L, Latagliata R, Castagnetti F, Ferrero D, Cavazzini F, Trawinska MM, Annunziata M, Stagno F, Tiribelli M, Binotto G, Crisà E, Musto P, Gozzini A, Cavalli L, Montefusco E, Iurlo A, Russo S, Cedrone M, Rossi AR, Pregno P, Endri M, Spadea A, Molica M, Giglio G, Celesti F, Sorà F, Storti S, D'Addosio A, Cambrin GR, **Isidori A**, Sica S, Abruzzese E, Specchia G, Rosti G, Alimena G. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. *Leuk Res*. 2014 Jul 7. pii: S0145-2126(14)00199-4. [Epub ahead of print]
17. Visani G, Malagola M, Guiducci B, Lucesole M, Loscocco F, Gabucci E, Paolini S, Piccaluga PP, **Isidori A**. Conditioning regimens in acute myeloid leukemia. *Expert Rev Hematol*. 2014 Aug;7(4):465-79.
18. Visani G, Ferrara F, Di Raimondo F, Loscocco F, Sparaventi G, Paolini S, Fuligni F, Gazzola A, Rossi M, Laginestra MA, Caraci MR, Riccardi C, Rocchi M, Visani A, Piccaluga PP, **Isidori A**. Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients. *Leukemia*, 2014, Apr;28(4):967-70. Epub 2014 Jan 20.
19. Visani G, Guiducci B, Giardini C, Loscocco F, Ricciardi T, **Isidori A**. Deferasirox improves hematopoiesis after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transpl*, 2014, Apr;49(4):585-7. Epub 2014 Jan 13.
20. **Isidori A**, Venditti A, Maurillo L, Buccisano F, Loscocco F, Manduzio P, Sparaventi G, Amadori S and Visani G. Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients. *Exp Rev Hematol*. 2013, Dec;6(6):767-84.
21. Visani G, **Isidori A**. Resistant chronic myeloid leukemia beyond TKI therapy: which role for omacetaxine? *Exp Opin Pharmacother*. 2013 oct 23 epub ahead of print.
22. **Isidori A**, Piccaluga PP, Loscocco F, Guiducci B, Barulli S, Ricciardi T, Picardi P, Visani G. High-dose therapy followed by stem cell transplantation in Hodgkin lymphoma: past and future. *Exp Rev Hematol*. 2013, Aug;6(4):451-64.
23. Latagliata R, Ferrero D, Iurlo A, Cavazzini F, Castagnetti F, Abruzzese E, Fava C, Breccia M, Annunziata M, Stagno F, Tiribelli M, Binotto G, Mansueto G, Gozzini A, Russo S, Cavalli L, Montefusco E, Gugliotta G, Cedrone M, Russo Rossi A, Avanzini P, Pregno P, Mauro E, Spadea A, Celesti F, Giglio G, **Isidori A**, Crugnola M, Calistri E, Sorà F, Storti S, D'Addosio A, Rege-Cambrin G, Luciano L, Alimena G. Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study. *Drugs Aging*. 2013 Aug;30(8):629-37.
24. Visani G, Picardi P, Guiducci B, Loscocco F, Giardini C, Lucesole M, Barulli S, Ricciardi T, **Isidori A**. Third party cord blood transplant boosts autologous hematopoiesis in a case of persistent bone marrow aplasia after double transplant failure for B-thalassemia major. *Mediterr J Hematol Infect Dis*. 2013 Apr 15;5(1):e2013029.

25. Latagliata R, **Isidori A**, Breccia M, Carmosino I, Vozella F, Volpicelli P, Finsinger P, Barulli S, Loglisci G, Santopietro M, Federico V, Diverio D, Nanni M, Mancini M, Visani G, Alimena G. Complete Clearance of Ph+ Metaphases after 3 Months Is a Very Early Indicator of Good Response to Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia. *Acta Haematol.* 2013; 129(2):126-134.
26. Visani G, Picardi P, Tosi P, Gonella R, Loscocco F, Ricciardi T, Malerba L, Guiducci B, Tomassetti S, Barulli S, **Isidori A**. Autologous stem cell transplantation for aggressive lymphomas. *Mediterr J Hematol Infect Dis.* 2012;4(1):e2012075.
27. Tosi P, Imola M, Mianulli AM, Tomassetti S, Merli A, Molinari A, Mangianti S, Ratta M, **Isidori A**, Visani G. Update on the role of autologous hematopoietic stem cell transplantation in multiple myeloma. *Mediterr J Hematol Infect Dis.* 2012;4(1):e2012069.
28. Olivieri A, Gini G, Bocci C, Montanari M, Trappolini S, Olivieri J, Brunori M, Catarini M, Guiducci B, **Isidori A**, Alesiani F, Giuliodori L, Marcellini M, Visani G, Poloni A, Leoni P. Tailored Therapy in an Unselected Population of 91 Elderly Patients with DLBCL Prospectively Evaluated Using a Simplified CGA. *Oncologist.* 2012;17(5):663-72.
29. Visani G, Sapienza MR, **Isidori A**, Tripodo C, Laginestra MA, Righi S, Sagramoso Sacchetti CA, Gazzola A, Mannu C, Rossi M, De Nictolis M, Valentini M, Donati M, Emiliani R, Alesiani F, Paolini S, Finelli C, Pileri SA, Piccaluga PP. SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis. *PLoS One.* 2011;6(11):e27560. Epub 2011 Nov 14.
30. Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Giardini C, Falcioni S, Cuberli F, Gobbi M, Sarina B, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD and **Isidori A**. BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant is safe and effective for resistant/relapsed lymphoma patients. *Blood.* 2011 Sep 22;118(12):3419-25.
31. Curti A, Ruggeri L, D'Addio A, Bontadini A, Dan E, Motta MR, Trabanelli S, Giudice V, Urbani E, Martinelli G, Paolini S, Fruet F, **Isidori A**, Parisi S, Bandini G, Baccarani M, Velardi A, Lemoli RM. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high-risk acute myeloid leukemia patients. *Blood.* 2011. Sep 22;118(12):3273-9.
32. Visani G, Breccia M, Montefusco E, Morra E, Santini V, **Isidori A**. The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. *Haematologica* 2011; 96(4):e23-4.
33. Malagola M, Tiribelli M, Russo D, Candoni A, Visani G and **Isidori A**. Myeloid sarcoma: the Clinician's point of view. *Leukemia Research and Treatment* 2011. Article ID 410291, 2 pages.
34. Visani G, **Isidori A**. Doxorubicin variants for hematological malignancies. *Nanomedicine (Lond).* 2011; 6(2):303-6.
35. **Isidori A**, Merli F, Angrilli F, Ferrara F, Alesiani F, Visani G. The incidence of *Pneumocystis jirovecii* pneumonia (PCP) is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin,

- vincristine and prednisolone (R-COMP 14) and adequate PCP prophylaxis. *Leuk Lymphoma*, 2011 Jan;52(1):148-9. Epub 2010 Nov 11.
36. Visani G, Breccia M, Gozzini A, Specchia G, Montefusco E, Morra E, Annunziata M, Camera A, Cavazzini F, Stagno F, Pregno P, Usala E, Santini V, Piccaluga PP, **Isidori A**. Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. *Am J Hematol* 2010 Dec;85(12):960-3.
 37. **Isidori A**, Visani G. Stem cell mobilization: the other side of the coin. *Br J Haematol*. 2010; 150(6):663-4
 38. Visani G, Piccaluga P, Malagola M, **Isidori A**. Efficacy of dasatinib in conjunction with alpha-interferon for the treatment of imatinib-resistant and dasatinib-resistant Ph+ acute lymphoblastic leukemia. *Leukemia*, 2009; 23(9):1687-8.
 39. Visani G, **Isidori A**. Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand. *Expert Rev Anticancer Ther*, 2009 Mar;9(3):357-63.
 40. **Isidori A**, Visani G. The prevention of alemtuzumab-induced cytomegalovirus reactivation: still a matter of debate. An update from Pesaro experience with once weekly intravenous ganciclovir. *Leuk Lymphoma*, 2009 Feb;50(2):294-6.
 41. Visani G, Ferrara F, Alesiani F, Ronconi S, Catarini M, D'adamo F, Guiducci B, Bernardi D, Barulli S, Piccaluga P, Rocchi M, **Isidori A**. R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study. *Leuk Lymphoma*, 2008 Jun;49(6):1081-6.
 42. Lorenzini S*, **Isidori A***, Catani L, Gramenzi A, Talarico S, Bonifazi F, Giudice V, Conte R, Baccarani M, Bernardi M, Forbes SJ, Lemoli RM, Andreone P. Stem cell mobilization and collection in patients with liver cirrhosis. *Aliment Pharmacol Ther*, 2008 May;27(10):932-9. *These author equally contributed to the manuscript
 43. Piccaluga PP, Martinelli G, **Isidori A**, Malagola M, Rondoni M, Paolini S, Amabile M, Iacobucci I, Baccarani M, Visani G. Long-term molecular complete remission with IFN-alpha in Ph+ adult acute lymphoid leukemia patients. *Leukemia*, 2008 Aug;22(8):1617-8.
 44. Visani G, Lucesole M, Guiducci B, Leopardi G, Giardini C, **Isidori A**. A diagnostic dilemma in stem cell transplantation for beta thalassemia major: progressive loss of take or pure red cell aplasia? *International Journal of Hematology*, 2007; 86(5): 461-462.
 45. **Isidori A**, Motta MR, Tani M, Terragna C, Zinzani PL Antonio Curti A, Rizzi S, Taioli S, Giudice V, D' Addio A, Gugliotta G, Conte R, Baccarani, M and Lemoli RM. Positive selection and transplantation of autologous highly purified CD133+ stem cells in resistant/relapsed chronic lymphocytic leukemia patients results in rapid hematopoietic reconstitution without an adequate leukemic cell purging. *Biology of Blood and Marrow Transplantation*, 2007 Oct;13(10):1224-32.
 46. Mele A, Offidani M, Visani G, Marconi M, Cambioli F, Nonni M, Catarini M, Brianzoni E, Berbellini A, Ascoli G, Brunori M, Agostini V, Corvatta L, **Isidori A**, Spinelli A, Gradari M, Leoni P. Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging

- and the follow-up of patients with multiple myeloma: a multicentre study on 397 scans. *Br J Haematol*, 2007 Mar;136(5):729-35.
47. Curti A, Aluigi M, Pandolfi S, Ferri E, **Isidori A**, Salvestrini V, Durelli I, Horenstein AL, Fiore F, Massaia M, Piccioli M, Pileri SA, Zavatto E, D'Addio A, Baccarani M, Lemoli RM. Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. *Leukemia*, 2007 Feb;21(2):353-5. Epub 2006 Dec 14.
 48. Visani G, Mele A, Guiducci B, D'Adamo F, Leopardi G, Barulli S, Malerba L, Lucesole M, Sparaventi G, Piccaluga PP, Guernaccini E, Agostinelli F, **Isidori A**. An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pretreated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab. *Leuk Lymphoma*, 2006, 47(12):2542-2546.
 49. Curti A, Pandolfi S, Valzasina B, Aluigi M, **Isidori A**, Ferri E, Salvestrini V, Bonanno G, Rutella S, Durelli I, Horenstein AL, Fiore F, Massaia M, Colombo MP, Baccarani M, Lemoli RM. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25⁻ into CD25⁺ T regulatory cells. *Blood* 2007; 109(7):2871-7.
 50. Visani G, Olivieri A, Malagola M, Brunori M, Piccaluga PP, Capelli D, Pomponio G, Martinelli G, **Isidori A**, Sparaventi G, Leoni P. Consolidation therapy for adult acute myeloid leukemia: A systematic analysis according to evidence based medicine. *Leuk Lymphoma* 2006, 47(6):1091-1102.
 51. Aluigi M, Fogli M, Curti A, **Isidori A**, Gruppioni E, Chiodoni C, Colombo MP, Versura P, D'Errico-Grigioni A, Ferri E, Baccarani M, Lemoli RM. Nucleofection is an efficient non-viral transfection technique for human bone marrow-derived mesenchymal stem cells. *Stem cells* 2006, 24:454-461.
 52. Curti A, Pandolfi S, Aluigi M, **Isidori A**, Alessandrini I, Chiodoni C, Testoni N, Colombo MP, Baccarani M, Lemoli RM. Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. *Exp Hematol* 2005, 33(12):1521-30.
 53. Mele A, Leopardi G, Sparaventi G, Nicolini G, D'Adamo F, Guiducci B, Barulli S, Malerba L, Stramigioli S, Talevi N, Politi P, **Isidori A**, Malagola M, Piccaluga P, Visani G. Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia. *Eur J Haematol* 74(4):277-81, 2005.
 54. Visani G, Guiducci B, D'Adamo F, Mele A, Nicolini G, Leopardi G, Sparaventi G, Barulli S, Malerba L, **Isidori A**, Malagola M, Piccaluga PP. Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma. *Leuk Lymphoma* 46(3):477-9, 2005.
 55. **Isidori A**, Tani M, Bonifazi F, Zinzani PL, Curti A, Motta MR, Rizzi S, Giudice V, Farese O, Rovito M, Alinari L, Conte R, Baccarani M, Lemoli RM. Phase II study of a single pegfilgrastim injection to mobilize stem cells into peripheral blood of pretreated lymphoma patients. *Haematologica* 90(2):225-231, 2005.

56. **Isidori A**, Bonifazi F, Visani G, Gherlinzoni F, Baccarani M, Lemoli RM. Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: a 10-year follow-up study of 118 patients. *Haematologica* 90(1):139-140, 2005.
57. Piccaluga PP, Martinelli G, Rondoni M, Malagola M, Gaitani S, **Isidori A**, Bonini A, Gugliotta L, Luppi M, Morselli M, Sparaventi G, Visani G, Baccarani M. Gentuzumab Ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcoma. *Leuk Lymphoma* 45(9): 1791-1795.
58. Visani G, Malagola M, Piccaluga PP, **Isidori A**. Low-dose Ara-C for myelodysplastic syndromes: is it still a current therapy? *Leuk Lymphoma* 45(8): 1531-1538, 2004.
59. Curti A, **Isidori A**, Ferri E, Terragna C, Neyroz P, Cellini C, Ratta M, Baccarani M, Lemoli RM. Generation of dendritic cells from positively selected CD14⁺ monocytes for anti-tumor immunotherapy. *Leuk Lymphoma* 45(7): 1419-1428, 2004.
60. Visani G, **Isidori A**, Grafone T, Tosi P, Santini V, Malagola M, Martinelli G, Piccaluga PP, Gaziev D, Ottaviani E, Sparaventi G, Tura S. No preferential sensitivity of t(8;21) acute myeloid leukemia cells to cytosine arabinoside in vitro: is intensity of therapy of high dose Ara-C crucial for response? *Leuk Lymphoma* 45(7): 1361-1364.
61. Curti A, Ferri E, Pandolfi S, **Isidori A**, Lemoli RM. Dendritic cell differentiation. *J Immunol* 172(1):3, 2004.
62. Lemoli RM, De Vivo A, Damiani D, **Isidori A**, Tani M, Bonini A, Cellini C, Curti A, Gugliotta L, Visani G, Fanin R, Baccarani M. Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective to support myeloablative chemotherapy in patients with hematological malignancies and poor peripheral blood stem cell mobilization. *Blood* 2003 Sep 1; 102(5):1595-1600.
63. Martinelli G, Ottaviani E, Buonamici S, **Isidori A**, Borsaru G, Visani G, Piccaluga PP, Malagola M, Testoni N, Rondoni M, Nucifora G, Tura S, Baccarani M. Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts. *Haematologica*, 88: 1221-1228, 2003.
64. Visani G, Mele A, Malagola M, **Isidori A**, Finelli C, Piccaluga PP. Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents. *Leukemia* 2003;17(8):1669-70.
65. Piccaluga PP, Visani G, **Isidori A**, Malagola M, Ascani S, Pileri SA. Microdose alpha-interferon shows clinical and antiangiogenic effect in extramedullary myeloid tumor: a case report. *Leukemia* 2003 May;17(5):986-7.
66. Martinelli G, Buonamici S, Visani G, Malagola M, Piccaluga PP, **Isidori A**, Bosi C, Bonifazi F, Soverini S, Terragna C, Amabile M, Giannini B, Baccarani M. Molecular monitoring of acute myeloid leukemia associated with inv(16): threshold of CBFbeta/MYH11 transcript copy number above which relapse occurs and below which continuous Complete Remission is likely. *Leukemia* 2003 Mar;17(3):650-1.

67. Visani G, **Isidori A**, Malagola M, Alberti D, Capdeville R, Martinelli G, Piccaluga PP, Amabile M, Guiducci B, Tura S, Baccarani M. Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190(BCR-ABL)-positive acute lymphoblastic leukemia. *Leukemia* 2002 Oct;16(10):2159-60.
68. Piccaluga PP, Visani G, Martinelli G, **Isidori A**, Malagola M, Rondoni M, Baccarani M, Tura S. Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia. *Leukemia* 2002 Sep;16(9):1880-1.
69. Martinelli G, Ottaviani E, Buonamici S, **Isidori A**, Malagola M, Piccaluga P, Baccarani M. Two more inv(16) acute myeloid leukemia cases with infrequent CBFbeta-MYH11 fusion transcript: clinical and molecular findings. *Haematologica* 2002 May;87(5):554-5.
70. Piccaluga PP, Visani G, Pileri SA, Ascani S, Grafone T, **Isidori A**, Malagola M, Finelli C, Martinelli G, Ricci P, Baccarani M, Tura S. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. *Leukemia* 2002 Sep;16(9):1609-14.
71. Buonamici S, Ottaviani E, Testoni N, Montefusco V, Visani G, Bonifazi F, Amabile M, Terragna C, Ruggeri D, Piccaluga PP, **Isidori A**, Malagola M, Baccarani M, Tura S, Martinelli G. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. *Blood* 2002 Jan 15;99(2):443-9.
72. Visani G, Buonamici S, Malagola M, **Isidori A**, Piccaluga PP, Martinelli G, Ottaviani E, Grafone T, Baccarani M, Tura S. Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study. *Leukemia* 2001 Nov;15(11):1696-700.
73. Visani G, Lemoli RM, **Isidori A**, Piccaluga PP, Martinelli G, Malagola M, Gugliotta L, Bonini A, Bonifazi F, Motta MR, Rizzi S, Castellani S, Tura S. Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients. *Bone Marrow Transplant* 2001; 27(8):829-35.
74. Visani G, Bernasconi P, Boni M, Castoldi GL, Ciolli S, Clavio M, Cox MC, Cuneo A, Del Poeta G, Dini D, Falzetti D, Fanin R, Gobbi M, **Isidori A**, Leoni F, Liso V, Malagola M, Martinelli G, Mecucci C, Piccaluga PP, Petti MC, Rondelli R, Russo D, Sessarego M, Specchia G, Testoni N, Torelli G, Mandelli F, Tura S. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia-analysis of 848 patients. *Leukemia* 2001 Jun;15(6):903-9.
75. Visani G, Milligan D, Leoni F, Chang J, Kelsey S, Marcus R, Powles R, Schey S, Covelli A, **Isidori A**, Litchman M, Piccaluga PP, Mayer H, Malagola M, Pfister C. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. *Leukemia* 2001 May;15(5):764-71.

76. Visani G, Pagano L, Pulsoni A, Tosi P, Piccaluga PP, Pastano R, Grafone T, Malagola M, **Isidori A**, Tura S. Chemotherapy of secondary leukemias. *Leuk Lymphoma* 2000 May;37(5-6):543-9.
77. Visani G, Gugliotta L, Tosi P, Catani L, Vianelli N, Martinelli G, Ottaviani E, Testoni N, Nocentini F, Pastano R, Piccaluga P, **Isidori A**, Grafone T, Tura S. All-trans retinoic acid significantly reduces the incidence of early hemorrhagic death during induction therapy of acute promyelocytic leukemia. *Eur J Haematol* 2000 Mar;64(3):139-44.
78. Visani G, Rosti G, Bandini G, Tosi P, **Isidori A**, Malagola M, Stanzani M, Martinelli G, Piccaluga P, Testoni N, Ricci P, Tura S. Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. *Br J Haematol* 2000 Jun;109(4):722-8.
79. Visani G, Martinelli G, Piccaluga P, Tosi P, Amabile M, Pastano R, Cavo M, **Isidori A**, Tura S. Alpha-interferon improves survival and remission duration in P-190BCR-ABL positive adult acute lymphoblastic leukemia. *Leukemia* 2000 Jan;14(1):22-7. (*Impact Factor: 6.612*)
80. Visani G, Ottaviani E, Zauli G, Tosi P, Pellacani A, **Isidori A**, Pierpaoli S, Tura S. All-trans retinoic acid at low concentration directly stimulates normal adult megakaryocytopoiesis in the presence of thrombopoietin or combined cytokines. *Eur J Haematol* 1999 Sep;63(3):149-53.
81. Visani G, Lemoli R, Tosi P, Martinelli G, Testoni N, Ricci P, Motta M, Gherlinzoni F, Leopardi G, Pastano R, Rizzi S, Piccaluga P, **Isidori A**, Tura S. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells. *Bone Marrow Transplant* 1999 Sep;24(5):467-72.

BOOK CHAPTERS

1. Visani G, Isidori A. Clinical Experience with Liposomal Doxorubicin. In: Handbook of Nanobiomedical Research - Fundamentals, Applications and Recent Developments, Volume 2. Torchillin V (Ed), World Scientific Pub Co Inc, ISBN: 978-981-4520-64-5 (hardcover).
2. Visani G, Minotti G, **Isidori A**. Anthracycline Cardiotoxicity. In: Cardiomyopathies - From Basic Research to Clinical Management, Veselka J (Ed), InTech, 2011. ISBN: 978-953-307-834-2.
3. **Isidori A**, Visani G. Stem Cell Mobilization: An Overview. In: Stem Cells and Cancer Stem Cells, 2012, Volume 2, Part 1, 51-60, Hayat, M.A. (Ed.). Springer. ISBN 978-94-007-2015-2.
4. Visani G, Loscocco F, Ricciardi T, Picardi P, Barulli S, Guiducci B and **Isidori A**. The Chemical Structure, Pharmacology and Adverse Effects of Imatinib. In: Imatinib: Chemical Structure, Pharmacology and Adverse Effects. Akhtari M and Elhemaidei I (Ed.), Nova Publishing Group, 2013. ISBN: 978-1-62808-304-0.
5. **Isidori A**, Loscocco F, Visani G. Chemokines for Stem Cell Mobilization: What's Next . In: New Developments in Chemokines Research. Sands E and Silver JM (Ed.) , Nova Publishing Group, 2013. ISBN: 978-1-62808-464-1

I hereby authorize the processing of my personal data pursuant to Italian law 196/03 on privacy.

Pesaro, 18 July 2017

Alessandro Isidori